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A B S T R A C T   
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide and has seriously 
threatened public health by causing significant morbidity and mortality. Patients with coronavirus disease 
(COVID-19) with preexisting endothelial dysfunction caused by aging, diabetes, hypertension, and obesity are at 
high risk for life-threatening thromboembolic complications. This suggests a possibility that reduced endothelial 
nitric oxide (NO) production and NO bioavailability could be a common underlying pathology for the pro-
gression of COVID-19. Increasingly, evidence from experimental and clinical studies of SARS-CoV-2 infection 
shows that NO inhibits the pathogenesis of COVID-19, including virus entry into host cells, viral replication, host 
immune response, and subsequent thromboembolic complications. Restoring NO bioavailability may have the 
potential to be a preventive or early-treatment option for COVID-19. This review aims to provide in-depth dis-
cussion of NO bioavailability to prevent SARS-CoV-2 infection, particularly by focusing on lifestyle factors such 
as nitrate-rich diets, physical exercise, and nasal breathing, which could be easily performed on a daily basis to 
boost NO bioavailability.   
1. Introduction 
The novel coronavirus disease (COVID-19), caused by the severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has swept 
worldwide and has seriously threatened public health by causing sig-
nificant morbidity and mortality [1]. Despite commencing vaccination, 
with initially satisfactory efficacy, recent emergence of variant strains 
necessitates further investigation to reevaluate vaccine efficacy and 
safety [2]. Therefore, confirmatory polymerase chain reaction tests to 
identify SARS-CoV-2 infection and basic preventive measures, such as 
social distancing and wearing a mask, remain important precautions 
against COVID-19 [3]. SARS-CoV-2 primarily infects the respiratory 
tract and often progresses rapidly to acute respiratory distress syndrome 
(ARDS), with subsequent systemic viral spread and cytokine storm to 
cause endotheliitis of the vasculature of the intestine, kidney, heart, and 
brain [4]. Healthy endothelial cells naturally produce and release nitric 
oxide (NO), which regulates vascular tone and inhibits platelet aggre-
gation and coagulation to maintain vascular integrity [5]. However, 
persistent endothelial injury in severe COVID-19 decreases endothelial 
NO generation, thereby disrupting vascular integrity and increasing 
systemic thromboembolic complications. In particular, COVID-19 pa-
tients with preexisting endothelial dysfunction (i.e., aging, diabetes, 
hypertension, and obesity) are likely to physically worsen than younger 
and healthy individuals [6–8]. Furthermore, epidemiological studies 
showed that SARS-CoV-2 infection causes greater morbidity and mor-
tality in males than in females due to less estrogen-mediated vascular 
endothelial protection in the former [9]. These observations suggest that 
endothelial dysfunction could be a common underlying pathology in 
patients at risk for COVID-19 [10]. Recent studies have shown that 
lifestyle factors, such as diet and physical exercise, have a considerable 
effect on increasing NO bioavailability and can prevent lifestyle-related 
diseases by compensating for impaired vascular endothelial NO pro-
duction [5]. Therefore, restoring NO bioavailability may be a potential 
preventive or early-treatment option for COVID-19. This review aims to 
provide an in-depth discussion of lifestyle factors to prevent SARS-CoV-2 
infection and its complications by boosting NO bioavailability. 
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2. Pleiotropic inhibitory effects of NO on the pathogenesis of 
COVID-19 
In a cyclic guanosine-3′,5′-monophosphate (cGMP)-dependent and 
-independent manner that inhibits viral enzymes and cellular host fac-
tors essential for the virus life cycle and subsequent host inflammatory 
response, NO inhibits most stages of the inflammatory process under-
lying COVID-19 (Fig. 1). 
2.1. Viral entry to the host cells 
In the respiratory tract, NO provides a first-line of defense against 
micro-organisms via its antiviral and antimicrobial activities. In 
airborne viral transmission to the airway, NO can physically remove the 
viral particles from the upper respiratory tract by activating ciliary 
movement [11] and mucus secretion in the airway epithelium [11,12]; 
aging and habitual smoking may eliminate this defensive ability and 
facilitate the viral invasion of the lower respiratory tract, where the 
virus can infect multiple cell types, including alveolar airway epithelial 
cells, alveolar macrophages, and vascular endothelial cells (Fig. 1). In 
the case of SARS-CoV-2, the viral spike (S)-protein, which is required for 
viral entry, has two regions, S1 and S2. S1 has a receptor-binding 
domain that mediates direct contact with the host cellular receptor, 
angiotensin-converting enzyme 2 (ACE2), whereas S2 is involved in 
subsequent membrane fusion [13]. Following receptor binding at the 
host cell membrane to form the S-protein–ACE2 complex, the S-protein 
is proteolytically cleaved at the S1/S2 and S2’ sites by the cellular 
protease, transmembrane protease serine 2 (TMPRSS2) [14,15], fol-
lowed by a conformational change that may cause a close apposition of 
S-protein to the cellular membrane. In this setting, the membrane fusion 
and viral entry are facilitated due to increasing lipophilicity when the 
cysteine residues of S-protein are palmitoylated. However, NO interferes 
with the fusion between the viral S-protein and the host cellular mem-
brane [16]. In vitro studies of SARS-CoV-1 have shown that in the 
presence of the NO donor, S-nitroso-N-acetylpenicillamine (SNAP), the 
exposed cysteine residues of the S-protein, following enzymatic priming 
by TMPRSS2, are competitively nitrosylated with palmitoylation, lead-
ing to the inhibition of membrane fusion and viral entry to the host cells 
[17]. Moreover, it may be possible that endosomal cathepsin L, an 
acid-activated cysteine protease and alternative enzyme for the mem-
brane fusion following endocytosis, could be nitrosylated at the cysteine 
residue in the active site of this enzyme to inhibit the ensuing viral 
replication and immune reaction (Fig. 1) [18]. 
2.2. Viral replication and innate immune response 
After SARS-CoV-2 enters the target cells, viral replication and the 
innate immune response are initiated, and SARS-CoV-2 is disassembled 
Fig. 1. SARS-CoV-2 entry to host cells, replication, recognition by innate immune system and subsequent inflammatory process 
The SARS-CoV-2 life cycle in the host cells and subsequent inflammatory process are described in detail in the text. 
SARS-CoV-2: severe acute respiratory syndrome coronavirus 2, TMPRSS2: transmembrane protease serine 2, ACE2: angiotensin-converting enzyme 2, ROS: reactive 
oxygen species, ARDS: acute respiratory distress syndrome, RIG-I: retinoic acid-inducible gene-I, MDA-5: melanoma differentiation-associated protein 5, MAVS: 
mitochondrial antiviral-signaling protein, IRF: interferon regulatory factor, TLR7/8: Toll-like receptor 7/8, MyD88: myeloid differentiation primary response 88, NF- 
kB: nuclear factor-kappa B, IL-6: interleukin-6, TNFα: tumor necrosis factor α, Ang I: angiotensin I:, Ang II: angiotensin II, Ang1-7: angiotensin 1-7, eNOS: endothelial 
nitric oxide synthase, AT1R: angiotensin II type I receptor, ADAM17: a disintegrin and metalloprotease 17, EGF: epidermal growth factor, EGFR: epidermal growth 
factor receptor, TNFR: tumor necrosis factor receptor, STAT3: signal transducer and activator of transcription 3, gp130: glycoprotein 130, ICAM: intercellular 
adhesion molecule, VCAM: vascular cell adhesion molecule, ISGs: interferon-stimulated genes. 
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to release nucleocapsid and viral RNA into the cytosol for translation 
and replication (Fig. 1). Translated viral proteins are then assembled in 
the endoplasmic reticulum to form new virions, which are then, released 
from the Golgi membrane system by exocytosis into the extracellular 
compartment for the propagation of infection in other target cells [19]. 
The SARS-CoV-1 genome encodes several non-structural proteins 
that are essential for the life cycle of the virus. Among them, the viral 3- 
chymotrypsin-like (3CL) cysteine protease controls coronavirus repli-
cation [17]. Similar to SARS-CoV-1, in SARS-CoV-2, the SARS-CoV-2 
3CL cysteine protease is an essential factor for viral replication in the 
host cell. Akaberi et al. showed that SARS-CoV-2 3CL cysteine protease, 
which cleaves viral polyproteins into functional polypeptides that are 
responsible for viral replication, is a possible target for S-nitrosylation, 
suggesting a potential mechanism of inhibitory action of NO on this 
cysteine protease to interrupt the viral life cycle. The in vitro study by 
Akaberi showed that the SARS-CoV-2 3CL recombinant protease was 
covalently inhibited by SNAP through the transfer of nitrosonium ion 
(NO+) to the protease cysteine residue; the observed reduction in 
SARS-CoV-2 protease activity was consistent with S-nitrosylation of the 
enzyme active site cysteine [20]. These observations suggest that 
S-nitrosylation of pathogenic cysteine protease plays an important role 
in host defenses if its catalytic site includes a cysteine residue [17]. 
On the other hand, in parallel with ongoing viral replication, the 
viral RNA genome released into the cytosol is detected by intracellular 
pattern-recognition receptors (PRRs), innate immune sensors such as 
endosomal Toll-like receptor, and cytosolic retinoic acid-inducible gene 
I-like receptor. Following PRR activation, molecular signaling cascades 
culminate in the activation of downstream transcription factors, such as 
nuclear factor-κB (NF-κB) and interferon (IFN) regulatory factors, to 
produce proinflammatory mediators and type I/III IFNs (Fig. 1) [19]. 
Innate immune responses mediated by PRRs following SARS-CoV-2 
infection activate NF-κB, which translocates to the nucleus and initi-
ates transcription of adhesion molecules such as intercellular adhesion 
molecule-1, vascular cell adhesion molecule-1, E-selectin, and P-selec-
tin, and inflammatory cytokines, such as interleukin-6 (IL-6). The serum 
levels of these adhesion molecules and cytokines are significantly 
increased in severe COVID-19, suggesting that NF-κB is the main regu-
lator of the inflammatory process of this infection [21]. 
Regulation of NF-κB activation by NO has been well investigated for 
its involvement in various physiological and pathological conditions 
[22]. NF-κB is the p50-p65 heterodimer and is sequestered in the cyto-
plasm by IκB inhibitors. When IκB is phosphorylated by the IκB-kinase 
complex (comprising three subunits, IKKα, IKKβ, and IKKγ), NF-κB is 
translocated to the nucleus for DNA binding, which initiates the pro-
duction of multiple proinflammatory mediators. S-nitrosylation of IKKβ 
at Cys179 and p50 at Cys62 inhibits NF-κB-dependent DNA binding, 
promoter activity, and gene transcription, leading to the subsequent 
inflammatory response [22]. In this context, NO-mediated inhibition of 
NF-κB pathway might be a potential therapeutic option for COVID-19 
[21]. 
2.3. 3. ACE2-angiotensin (1–7)-Mas axis 
Another notable pathway for COVID-19 progression is the ACE2- 
angiotensin (1–7)-Mas axis (Fig. 1). ACE2 catalyzes the conversion of 
angiotensin-II (Ang-II) to Ang (1–7), which stimulates a transmembrane 
receptor, Mas, and initiates the Akt phosphorylation cascade for the 
activation of endothelial NO synthase (eNOS) to increase NO production 
[23]. SARS-CoV-2 infection downregulates ACE2 expression by inter-
nalizing it with virus particles from the host cell surface and fails to 
catalyze the conversion of Ang-II to Ang (1–7), resulting in Ang-II 
accumulation, resultant increased reactive oxygen species production 
through the activation of nicotinamide adenine dinucleotide phosphate 
oxidase, and generation of peroxynitrite by consuming eNOS-derived 
NO. The accumulation of Ang-II under these conditions can induce 
vasoconstriction and act as a proinflammatory cytokine when bound to 
the Ang-II type 1 receptor (AT1R). This Ang II–AT1R signaling axis ac-
tivates a disintegrin and metalloprotease 17, which digests and releases 
the membrane forms of epidermal growth factor family members, 
interleukin-6 receptor, and tumor necrosis factor-α, followed by gene 
expression for a broad range of proinflammatory cytokines and che-
mokines, adhesion molecules, and acute-phase protein via the triggering 
of transcriptional factors, such as NF-κB and signal transducer and 
activator of transcription-3 (Fig. 1) [24]. 
The in vitro study by Leclerc et al. showed that the NO donor, sodium 
nitroprusside, dose-dependently inhibited the binding affinity of AT1R 
with Ang II by S-nitrosylation of AT1R at cysteine 289 [25]. Further-
more, Pinherio reported that treatment of rats with oral nitrite increased 
circulating S-nitrosothiol levels and reduced Ang-II-induced vasocon-
striction with increased aortic protein kinase C (PKC) nitrosylation [26]. 
These results suggest that the potential beneficial effects of NO may 
outweigh the deleterious effects of Ang-II in COVID-19 progression. 
2.4. NO as vasodilator and antiplatelet agent 
In the progressive stage of COVID-19, vascular endothelial 
dysfunction followed by thrombus formation and life-threatening blood 
coagulation are the underlying pathologies [10]. Inorganic nitrate/ni-
trite ingestion, via diet or supplementation, inhibits platelet reactivity 
and aggregation via cGMP-mediated reduction of platelet P-selectin 
expression in vitro and in vivo [27]. Srihirun et al. further suggest that 
deoxygenated erythrocytes reduce nitrite in the circulation, and subse-
quent NO-mediated activation of soluble guanylyl cyclase modulates 
platelet activation and blood clotting within the various parts of the 
vascular bed [28]. Moreover, NO can lower pulmonary vascular resis-
tance and decrease pulmonary edema due to its potent and selective 
pulmonary vasodilation, which enhances ventilation/perfusion match-
ing and may improve respiratory symptoms [27]. 
3. Lifestyle factors that boost NO bioavailability 
Based on the proposed inhibitory effects of NO on COVID-19, ther-
apeutic strategies using NO may be strongly recommended, particularly 
for COVID-19 patients with endothelial dysfunction. NO-mediated pre-
vention of SARS-CoV-2 infection could be facilitated by lifestyle factors, 
such as nitrate-rich diets, physical exercise, and nasal breathing 
[29–31], which are eventually integrated in cGMP-dependent and -in-
dependent pathways (Fig. 2). The cGMP-independent pathway consti-
tutes posttranslational protein modification (S-nitrosylation) through 
the covalent attachment of NO+ to reactive cysteine residues of target 
proteins such as receptors, enzymes, and transcription factors that 
mediate COVID-19 pathogenesis. However, the cGMP-dependent 
pathway is mediated by binding of NO to the heme moiety of its 
effector (soluble guanylyl cyclase), followed by subsequent activation of 
cGMP-dependent signaling, leading to vascular dilatation and antith-
rombotic properties [5]. 
3.1. Enterosalivary nitrate–nitrite–NO pathway 
Apart from the enzymatic L-arginine/NOS pathway, the enter-
osalivary nitrate–nitrite–NO pathway is an alternative for gastric and 
systemic NO generation [32]. Abundant dietary nitrate in green leafy 
vegetables is absorbed from the upper gastrointestinal tract into the 
systemic circulation, wherein approximately 60% of nitrate is excreted 
renally within 48 h [33] and 25% is actively absorbed from the circu-
lation by the salivary gland and secreted into saliva. Dietary and 
salivary-derived nitrates are reduced to nitrite in the oral cavity by 
commensal bacteria residing on the lingual surface [34]. Upon deglu-
tition into the stomach, the nitrite is reduced by H+ in the gastric juice to 
form nitrous acid, which decomposes to NO and other nitrogen oxides, 
such as dinitrogen trioxide (N2O3) and NO2. N2O3 can donate an NO +
for subsequent S-transnitrosylation in gastric and systemic NO 
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physiology. Pinherio et al. reported that antiseptic mouthwash disrupts 
the enterosalivary nitrate circulation, thereby decreasing the levels of 
nitrite and S-nitrosothiol in the plasma and vascular tissue that di-
minishes the blood pressure-lowering effect of dietary nitrate in hy-
pertensive rat models [35]. Montenegro et al. reported results from a 
human study that an increase in gastric pH induced by pretreatment 
with proton-pump inhibitor not only blunts intragastric NO generation 
following nitrate/nitrite ingestion but also decreases plasma levels of 
S-nitrosothiol and its hypotensive effect that reflects a downstream NO 
signaling pathway [36]. These observations suggest that nitrate-rich 
diets (i.e., beetroot, spinach, etc.), saliva secretion during frequent 
chewing, oral commensal bacteria, and gastric acidic environment are 
essential to boost NO bioavailability through the enterosalivary nitra-
te/nitrite/NO pathway [37–39]. 
Furthermore, beetroot juice, which contains nitrate and antioxidant 
polyphenols [40], and co-ingestion of nitrate/nitrite with drugs con-
taining structural sulfhydryl compounds (i.e., ACE inhibitor, captopril 
[30], and antiplatelet drug, thienopyridine [29,41]) can increase the 
plasma levels of S-nitrosothiols, which function as an intermediary 
receiver of NO+ that is generated in the stomach to nitrosylate target 
proteins and peptides, such as albumin and glutathione, that contain 
cysteine residues to boost peripheral NO bioavailability [42]. 
On the other hand, nitrate and nitrite contents in drinking water and 
foods have been limited by regulations in many countries because of 
their acute and chronic toxicities such as methemoglobinemia and 
cancer. However, the report on methemoglobinemia is a very limited 
case of infants fed formula milk prepared with bacterially contaminated 
well water [43]. Chronic exposure to nitrate in foods (e.g., high red meat 
intake) has been linked to increased risk of cancer, whereas, the World 
Cancer Research Fund Continuous Update Report in 2015 reported no 
consistent epidemiological evidence of an increased risk of human 
cancer due to nitrate consumption (e.g., fruits and vegetables) [44]. 
Taken together, these physiological, nutritional, and pharmacolog-
ical factors involved in the enterosalivary pathway could possibly 
mediate the S-nitrosylation of the viral proteins and cellular host factors 
essential for the virus life cycle to prevent SARS-CoV-2 infection. 
3.2. Physical exercise 
Shear stress induced by pulsatile mechanical stimulus to the vascular 
endothelium, particularly during exercise, enhances transcriptional and 
protein levels of eNOS, which increases NO production to regulate 
vascular tone in response to endurance exercise, and maintains the 
integrity of the vascular endothelial barrier [45]. Therefore, aerobic 
physical exercise (e.g., walking and jogging) possibly inhibits 
SARS-CoV-2 infection through the NO-mediated mechanism shown in 
Fig. 1 [46,47]. 
In addition to vascular eNOS-derived NO generation during aerobic 
exercise, resistance exercise creates a shift toward a different biological 
mechanism for NO generation by non-enzymatic reduction of nitrate/ 
nitrite stored in skeletal muscle [48], which might facilitate 
NO-mediated prevention of SARS-CoV-2 infection, particularly during 
anaerobic resistance exercise (e.g., weight lifting and sprinting). Basal 
and postprandial (particularly nitrate-rich foods) concentrations of ni-
trate are substantially higher in human skeletal muscle tissue than in 
plasma following active transport from the circulating blood, suggesting 
that skeletal muscle tissue may serve as an endogenous nitrate reservoir 
[49]. Moreover, oxidation of NO produced by muscular nNOS may 
contribute to the increased levels of nitrate stores in the skeletal muscle. 
Piknova et al. found that a very large decrease in muscle nitrate levels 
immediately after exercise is accompanied by a transient increase in the 
muscle tissue nitrite level, which is then reduced to NO formation at 
least partially by xanthine oxidoreductase under conditions of slight 
lowering of pH and hypoxia that is induced by resistance exercise [50] 
and contributing to basal vascular endothelial physiology and 
NO-mediated mitochondrial ergogenic effect [51,52]. Furthermore, this 
would generate the possibility of NO-mediated cytoprotection against 
SARS-CoV-2 during exercise. 
Fig. 2. Lifestyle factors boost NO bioavailability to prevent COVID-19 progression 
Inhibitory effects of lifestyle factors on COVID-19 progression are transmitted via NO-mediated signaling and finally integrated to cGMP-dependent and -independent 
pathways. 
NO: nitric oxide, SNAP: S-nitroso-N-acetylpenicillamine, SNP: sodium nitroprusside, NOS: NO synthase, Hb: hemoglobin, Mb: myoglobin, XOR: xanthine oxidore-
ductase,Fe–NO: nitrosyl iron, N2O3: dinitrogen trioxide, SNO: S-nitrosothiol, cyclic cGMP: cyclic guanosine-3′, 5′-monophosphate, COVID-19: coronavirus disease. 
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Erythrocytes can store nitrate/nitrite derived from diet and 
endothelium-derived NO oxidation. Nitrite consumption in blood from 
artery to vein is observed at rest, and is further enhanced during hypoxia 
and exercise, suggesting that nitrite generates NO following exercise but 
even at resting in the presence of deoxyhemoglobin due to its reductase 
activity; however, in the presence of oxyhemoglobin, this phenomenon 
is markedly reduced due to the rapid NO-scavenging characteristics of 
oxyhemoglobin [53]. However, the question remains as to how the NO 
produced by deoxyhemoglobin can escape scavenging by oxyhemo-
globin; some hypotheses were proposed to explain how this might occur. 
The reaction of nitrite and deoxyhemoglobin generates less reactive 
intermediates, such as N2O3 and/or S-nitroso-hemoglobin, which allow 
escape from erythrocyte and subsequent dissociation to release NO+ that 
is responsible not only for physiological effects, such as vasodilatation 
and antiplatelet action [54], but also possibly for an inhibitory effect 
against SARS-CoV-2 infection. 
3.3. NO inhalation therapy and nasal breathing 
NO inhalation therapy (≥80 ppm) for patients with SARS-CoV- 
induced ARDS was previously performed during the 2002–2004 SARS 
outbreak, and preliminary studies showed that NO inhalation showed a 
promising potency to improve oxygenation and decrease lung infiltra-
tion by lowering pulmonary vascular resistance and alveolar edema via 
improved ventilation/perfusion mismatch and inhibition of neutrophil 
activation and subsequent proinflammatory cytokine release [55]. 
Moreover, inhaled NO has a wide range of systemic effects as an 
airborne messenger via cGMP-dependent and cGMP-independent 
mechanisms leading to decreased systemic vascular tone, reduced risk 
of thrombosis, and prevention of abnormal leukocyte adhesion to the 
endothelium [39]. Given the common pathological processes of ARDS 
between SARS and COVID-19, NO inhalation is expected to be effective 
for COVID-19 ARDS. Recently, a small portable NO inhalation device, 
which is convenient to carry, was invented to prevent SARS-CoV-2 
infection from the upper respiratory tract, particularly for healthcare 
workers who are in close contact with COVID-19 patients [56]. This 
clinical trial is currently ongoing to test its efficacy and safety against 
SARS-CoV-2. 
Thus, nasal breathing may be considered an additional lifestyle 
factor to boost NO bioavailability for preventing SARS-CoV-2 infection 
in the upper airways [31]. The nasal cavity fulfills important physio-
logical functions by filtering, warming, and humidifying inhaled air and 
produces NO in high quantities in the upper airways. Tornberg et al. 
reported that nasal breathers have higher NO levels in the respiratory 
tract than mouth breathers [57]. Although the NO values in the exhaled 
air to be measured depend on the method used and varies among lab-
oratories, recent studies have shown that oral NO ranges from 4 to 160 
ppb, whereas nasal NO concentrations vary from 200 to 2000 ppb. 
Paranasal sinuses are the major source of NO, sometimes having NO 
concentrations of 5–20 ppm in healthy adults. However, NO concen-
trations apparently decrease after entry into the nasal cavity through the 
communicating ostia during nasal inhalation. Despite lower nasal NO 
concentrations than those used for NO inhalation therapy for ARDS 
patients, clear effects of NO bioavailability on arterial oxygenation and 
pulmonary arterial pressure using inhaled NO concentrations of 10–100 
ppb have been reported [58–60] with similar NO levels as those that we 
breathe through the nose. Furthermore, Weitzberg and Lundberg re-
ported that humming causes a 15-fold increase in nasal NO compared 
with quiet exhalation (252 ± 63 ppb vs. 17 ± 3 ppb) due to 
humming-induced air oscillation between the sinuses and nasal cavity 
[61], suggesting that nasal breathing provides potential benefits for the 
early prevention of SARS-CoV-2 infection. 
4. Conclusion 
To summarize, the preventive strategies against COVID-19 that are 
proposed herein are lifestyle factors (nitrate-rich diets, exercise, and 
nasal breathing) that can be easily followed every day. These strategies 
potentially provide additional benefits for preventing lifestyle-related 
diseases (i.e., diabetes, hypertension, metabolic syndrome) and should 
be analyzed for their preventive efficacy against COVID-19, and if the 
efficacy is confirmed, they should be implemented in the clinical setting 
in the near future. 
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